NPI: 1821478975 · BOWLING GREEN, KY 42103 · Corporate Health Clinic/Center · NPI assigned 06/04/2015
Authorized official LAWLESS, MICHELE controls 20+ related entities in our dataset. Read more
| Authorized Official | LAWLESS, MICHELE (EXECUTIVE VICE PRESIDENT) |
| NPI Enumeration Date | 06/04/2015 |
Other providers sharing the same authorized official: LAWLESS, MICHELE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 2,298 | $89K |
| 2019 | 3,508 | $157K |
| 2020 | 8,772 | $221K |
| 2021 | 10,648 | $293K |
| 2022 | 17,701 | $356K |
| 2023 | 25,668 | $389K |
| 2024 | 21,307 | $318K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17,115 | 14,326 | $490K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5,389 | 4,362 | $378K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 7,650 | 6,013 | $251K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6,768 | 5,674 | $190K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3,322 | 2,877 | $149K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 10,144 | 8,801 | $137K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 762 | 598 | $70K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1,317 | 1,085 | $65K |
| 0002A | 497 | 486 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,366 | 1,118 | $17K |
| 0001A | 463 | 444 | $17K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 480 | 457 | $8K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 85 | 74 | $6K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 641 | 546 | $5K |
| 0003A | 169 | 160 | $4K | |
| 0054A | 113 | 107 | $3K | |
| 0004A | 173 | 135 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 77 | 67 | $3K |
| 87807 | 248 | 204 | $2K | |
| 0071A | 63 | 56 | $2K | |
| 0124A | 105 | 70 | $2K | |
| 0072A | 31 | 31 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 38 | 38 | $1K |
| 90686 | 40 | 38 | $778.50 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 14 | 12 | $316.38 |
| 90656 | 12 | 12 | $267.85 | |
| 71046 | Radiologic examination, chest; 2 views | 13 | 13 | $144.85 |
| 81003 | 102 | 80 | $46.23 | |
| 3074F | 8,548 | 7,084 | $17.96 | |
| 3078F | 7,010 | 5,847 | $12.48 | |
| 3079F | 2,973 | 2,455 | $8.44 | |
| 1125F | 1,347 | 1,149 | $4.43 | |
| 3075F | 610 | 493 | $1.30 | |
| 3077F | 420 | 364 | $1.11 | |
| 1159F | 2,920 | 2,557 | $1.09 | |
| 3008F | 4,041 | 3,484 | $0.42 | |
| 1036F | 3,416 | 2,916 | $0.29 | |
| 0521F | 724 | 598 | $0.27 | |
| 3080F | 93 | 78 | $0.22 | |
| 1160F | 188 | 158 | $0.10 | |
| 1034F | 415 | 356 | $0.08 |